GLI1 and medulloblastoma: As Hck may also enhance Gli1 activities with kinase-independent activities, specific inhibitors disrupting the Hck–Gli1 feedback loop would be more effective in inhibiting Shh-type medulloblastoma cancer progression than general kinase inhibitors.